<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;ACR Appropriateness Criteria&amp;reg; recurrent rectal cancer.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Konski AA, Herman JM, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Fowler KJ, Goodman KA, Jabbour SK, Jones WE III, Koong AC, Kumar R, Lee P, Rodriguez-Bigas M, Small W Jr, Suh WW, Expert Panel on Radiation OncologyâGastrointestinal. ACR Appropriateness CriteriaÂ® recurrent  rectal cancer [online publication]. Reston (VA): American College of Radiology (ACR); 2014. 11 p.  [44 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xA;&lt;p&gt;This guideline updates a previous version: Konski AA, Suh WW, Blackstock AW, Herman JM, Hong TS, Poggi MM, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. ACR Appropriateness Criteria&amp;reg; recurrent rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. 9 p. [43 references]&lt;/p&gt;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;ACR Appropriateness Criteria&amp;reg;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Clinical Condition&lt;/span&gt;: Recurrent Rectal Cancer&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 1&lt;/span&gt;: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago patient underwent a low anterior resection (pT3N0) and 6 months of adjuvant chemotherapy. Endoscopic ultrasound (EUS) now shows an anastomotic recurrence 6 cm above the anal verge. Biopsy positive for adenocarcinoma. No sites of metastatic disease. Tumor currently unresectable and nonobstructing. KPS 90.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 1: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago patient underwent a low anterior resection (pT3N0) and 6 months of adjuvant chemotherapy. Endoscopic ultrasound (EUS) now shows an anastomotic recurrence 6 cm above the anal verge. Biopsy positive for adenocarcinoma. No sites of metastatic disease. Tumor currently unresectable and nonobstructing. KPS 90.&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;40%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;10%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Initial Radiation Therapy Treatment&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30.6 Gy in 1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;40.8 Gy in 1.2 Gy BID with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis with FOLFOX chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;This treatment is preferred only on clinical trial.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;59.4-64.8 Gy/1.8 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;59.4-64.8 Gy/1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;SBRT to rectal lesion&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;External beam RT +/- concurrent chemotherapy with IORT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The need for IORT is based on the response to neoadjuvant therapy.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Surgery&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Preoperative RT +/&amp;ndash; 5-FU-based chemotherapy and reevaluate operability&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;9&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tumor excision and abdominal-perineal resection (APR) before external beam RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No surgery&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;5-FU-based Chemotherapy Timing&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4-6 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;12 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Induction chemotherapy prior to RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 2&lt;/span&gt;: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago the patient underwent a low anterior resection (pT3N0) and 6 months of adjuvant chemotherapy. EUS now shows an anastomotic recurrence 6 cm above anal verge. Biopsy positive for adenocarcinoma. Lesion not fixed to the pelvic sidewall on physical examination and CT. Patient now has a biopsy-proven resectable liver metastasis involving the right lobe (5 cm). KPS 90.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 2: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago the patient underwent a low anterior resection (pT3N0) and 6 months of adjuvant chemotherapy. EUS now shows an anastomotic recurrence 6 cm above anal verge. Biopsy positive for adenocarcinoma. Lesion not fixed to the pelvic sidewall on physical examination and CT. Patient now has a biopsy-proven resectable liver metastasis involving the right lobe (5cm). KPS 90.&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;40%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;10%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiation Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30.6 Gy in 1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2 &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;40.8 Gy in 1.2 Gy BID with 5-FU based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2 &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis with FOLFOX chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;This treatment is preferred only on clinical trial.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;SBRT to rectal lesion&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;External beam RT +/- concurrent chemotherapy with IORT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The need for IORT is based on the response to neoadjuvant therapy.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Treatment of Rectal Primary&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Preoperative RT +/&amp;ndash; 5-FU-based chemotherapy and reevaluate operability&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Resection of primary rectal tumor +/- IORT boost followed by adjuvant chemoradiation (5-FU-based)&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No surgery &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Treatment of Liver Metastasis&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;After resection of primary rectal tumor&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;5&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At the same time as the resection of the primary rectal tumor&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;7&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;After 3 to 6 months post-surgical chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;6&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Before resection of primary site, after preoperative RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Before resection of primary site, before preoperative RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;5-FU-based Chemotherapy Timing&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4 to 6 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;12 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Induction chemotherapy prior to RT/surgery&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 3&lt;/span&gt;: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago underwent a low anterior resection after preoperative chemotherapy and radiotherapy for a (pT3N1) rectal cancer and 6 months of adjuvant chemotherapy. EUS now shows an anastomotic recurrence 6 cm above the anal verge. Biopsy positive for adenocarcinoma. No sites of metastatic disease. KPS 90.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 3: 56-year-old patient with recurrent rectal bleeding and pain with defecation. Two years ago underwent a low anterior resection after preoperative chemotherapy and radiotherapy for a (pT3N1) rectal cancer and 6 months of adjuvant chemotherapy. EUS now shows an anastomotic recurrence 6 cm above the anal verge. Biopsy positive for adenocarcinoma. No sites of metastatic disease. KPS 90.&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;40%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;10%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Initial Radiation Therapy Treatment&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30 Gy/3.0 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;30.6 Gy in 1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;40.8 Gy in 1.2 Gy BID with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4/1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;50.4 Gy/1.8 Gy to pelvis with FOLFOX chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;This treatment is preferred only on clinical trial.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;59.4-64.8 Gy/1.8 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;59.4-64.8 Gy/1.8 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;SBRT to rectal lesion&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;External beam RT +/- concurrent chemotherapy with IORT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider this treatment only at experienced centers.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Surgery&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Preoperative RT +/- 5-FU-based chemotherapy and reevaluate operability&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tumor excision and abdominal-perineal resection (APR) before external beam RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No surgery&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;5-FU-based Chemotherapy Timing&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;4 to 6 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;12 months after therapy to primary&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Induction chemotherapy prior to RT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Variant 4&lt;/span&gt;: 56-year-old male with severe pain that radiates to perineal region. Two years ago the patient was diagnosed with T3N1 rectal cancer 6 cm from anal verge. Underwent an abdominal-perineal resection, pelvic RT totaling 50.4 Gy plus 5-FU, followed by 6 months of adjuvant chemotherapy. CT of abdomen and pelvis reveal rectal mass (4 cm) invading bony pelvis at sciatic notch. No sites of metastatic disease. KPS 90.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Variant 4: 56-year-old male with severe pain that radiates to perineal region. Two years ago the patient was diagnosed with T3N1 rectal cancer 6 cm from anal verge. Underwent an abdominal-perineal resection, pelvic RT totaling 50.4 Gy plus 5-FU, followed by 6 months of adjuvant chemotherapy. CT of abdomen and pelvis reveal rectal mass (4 cm) invading bony pelvis at sciatic notch. No sites of metastatic disease. KPS 90.&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;40%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Treatment&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;10%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Rating&lt;/th&gt;&#xD;&#xA;            &lt;th width=&quot;50%&quot; class=&quot;Center&quot; valign=&quot;top&quot; scope=&quot;col&quot;&gt;Comments&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Radiation Therapy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;10-30 Gy/2.0 Gy to pelvis&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;10-30 Gy/2.0 Gy to pelvis with 5-FU-based chemotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;10-30 Gy/2.0 Gy to pelvis with 5-FU-based chemotherapy + IORT boost to pelvic sidewall&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Permanent radioactive implant of symptomatic lesion&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hyper- or standard- dose radiation fractionated to 30-40 Gy with 5-FU-based chemotherapy followed by reevaluation for surgical resection +/- IORT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;7&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;SBRT to rectal lesion &lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Surgery&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Reevaluate operability after external beam RT +/&amp;ndash; 5-FU&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;8&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Surgery post external beam RT +/- 5-FU +/- IORT boost&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;7&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Attempt tumor removal + IORT&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Reevaluate operability after permanent implant&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;middle&quot;&gt;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;    &lt;tfoot&gt;&#xD;&#xA;    &lt;tr&gt;&#xD;&#xA;        &lt;th valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Scale&lt;/span&gt;: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate&lt;/th&gt;&#xD;&#xA;    &lt;/tr&gt;&#xD;&#xA;    &lt;/tfoot&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;Note: Abbreviations used in the tables are listed at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary of Literature Review&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Introduction/Background&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Local or regional failure in rectal cancer presents a major dilemma. Therapy strategies for patients with local pelvic recurrences are individualized, depending on the site of local recurrence as well as the type of therapy previously received.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For new patients with recurrences at the anastomoses from a previous low anterior resection who had not received adjuvant radiation therapy (RT) previously, appropriate treatment would include either re-resection followed by postoperative combined-modality therapy (CMT) or a preoperative CMT approach followed by surgical intervention with or without intraoperative radiation if technically and medically feasible. For those patients having previously received pelvic radiation, limited reirradiation with our without chemotherapy and intraoperative radiation therapy (IORT) is an option.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Radiation Versus Chemoradiation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the setting of a patient presenting with a local pelvic or perineal scar recurrence after abdominal-perineal resection (APR), surgery remains an option, followed by CMT if the patient had not previously been treated. Type of primary surgery, symptoms, location of the recurrence, and whether the tumor is fixed to adjacent structures affect overall prognosis, with a median survival time of 28 months with a R0 resection compared to 12 months with an R1 or R2 resection. A high postoperative morbidity rate can occur in patients undergoing radical resection, including sacrectomy. Alternatively, preoperative RT with curative intent could also be given for local recurrences in the setting of a previous APR. Patients with poor performance status could be treated with palliative CMT alone. The chemotherapy agent 5-fluorouracil (5-FU) is generally incorporated with RT in an effort to increase radio responsiveness; however, the effectiveness of chemoradiation compared to radiation alone in this setting or in patients with other sites of pelvic recurrence is debatable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Importance of Preoperative or Definitive Radiation (with or without Chemotherapy) in Patients with Locally Recurrent Rectal Cancer&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One study compared the results of preoperative RT and surgery to surgery alone in patients with recurrent rectal cancer. Local control after preoperative treatment was statistically significantly higher at 3 and 5 years compared to the surgery-alone group. There was, however, no difference in overall or metastases-free survival between the groups. Another study evaluated preoperative and perioperative risk factors for morbidity and mortality after irradiation and surgery in patients &amp;gt;75 years of age with locally advanced or recurrent rectal cancer. They reported a 46% R0 resection rate in patients with recurrent cancers. Margin status was found to be predictive of disease-free survival rates in patients undergoing aggressive surgery including sacrectomy for recurrent rectal cancer. They did, however, report a 42% significant complication rate with patients undergoing sacrectomy having a higher complication rate. Surgery also provided a longer median survival time&amp;mdash;21 months, compared to 12 months for patients receiving combined RT and chemotherapy alone&amp;mdash;in a population-based study of 141 patients with recurrent rectal cancers. A 57% 5-year survival rate was reported in 25 patients undergoing a curative resection. Chemoradiotherapy with or without surgery was found to be beneficial in a trial of 67 patients treated with locally recurrent rectal cancer not receiving previous therapy with a 5-year overall survival rate of 48.9%. Interestingly, no statistically significant difference was found when comparing clinical outcomes between the patients receiving chemoradiotherapy with and without surgery.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of three-dimensional (3-D) conformal RT combined with folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX4) chemotherapy was investigated in 48 patients with unresectable recurrent rectal cancer. A &amp;gt;90% relief in pain with a 56.5% overall response rate was reported in the study group. However, more peripheral neuropathy in the study group was reported compared to the control group. Another group of authors also reported on the use of an oxaliplatin-containing regimen in patients with recurrent rectal cancer without prior RT. Complete clinical response was documented in 14% with a partial remission in 61% with an overall and disease-free survival of 45% and 14%, respectively (See Variant 1 and Variant 2 above).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Reirradiation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients with locally recurrent rectal cancer following high-dose pelvic radiation, management decisions have generally been directed towards palliative care employing diverting colostomies and chemotherapy. Although historically considered unsafe, reirradiation in the pelvis has been investigated in selected patients with locally recurrent rectal cancer and found to be reasonably well tolerated and can provide symptomatic relief in most patients. Additionally, a significant percentage of patients were able to undergo radical surgical salvage, with a 2-year survival rate of 66% in this group. An update from the same institution included 52 patients with recurrent rectal cancer who underwent reirradiation. A 15% bowel obstruction rate and a 7% fistula rate were reported when reirradiation was combined with surgery. The median reirradiation dose was 30.6 Gy. Twenty-two patients were treated in a hyperfractionated approach (1.2 Gy twice daily [BID]). Total cumulative doses ranged from 66.6 to 104.9 Gy with a median total dose of 84.4 Gy. The whole pelvis was not treated, and small bowel and bladder were excluded from the reirradiation field. The actuarial survival at 2 years was 25%, decreasing to 14% at 3 years. Bleeding was stopped in 100% of patients with palliation of pain seen in 65%. The incidences of Radiation Therapy Oncology Group (RTOG&amp;reg;) grade 3 and 4 late toxicity were 23% and 10%, respectively. The use of hyperfractionated RT resulted in reduced late toxicity in comparison to conventionally treated patients receiving once-daily irradiation. One study treated 58 patients who had rectal cancer recur after previous RT, delivering either 23.4 Gy in 1.8 Gy fractions or 1.2 Gy BID to 40.8 Gy. Intraoperative electron beam radiation therapy (IOERT) was delivered in 20 cases. They reported a 40% 5-year overall survival rate, with 5-year overall survival greater in patients who also underwent an R0 resection. A 60% overall response rate and 93% clinical response rate was found in 72 patients receiving 3-D conformal accelerated hyperfractionated RT, 1.2 Gy BID to 36 Gy, with unresectable patients receiving 51.6 to 56.4 Gy, combined with capecitabine. Grade 3&amp;ndash;4 diarrhea was noted in 9.7%, with late small-bowel obstruction seen in 1.4%.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Another study evaluated the response rate, resectability rate, local control, and treatment-related toxicity of preoperative hyperfractionated chemoradiation for patients with locally recurrent rectal cancer who had received previous radiation. They found that 86.4% of patients had treatment completed without any interruption, with only a 5.1% rate of acute lower gastrointestinal toxicity. The authors also reported a 39% 5-year survival rate. Another study reported a 72% good or complete palliative effect for a median of 6 months in patients receiving reirradiation and hyperthermia. A group of researchers reported a median overall survival time of 38 months with an estimated 40% 5-year survival rate in patients having resection of isolated pelvic recurrences. In this study, 56 of 88 patients had additional radiation, including 24 treated with brachytherapy, eight treated with IORT, and 24 treated with external beam radiation. Preoperative carcinoembryonic antigen and final margin status were statistically significant predictors of outcome.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Another study reported on a cohort of 577 patients with local recurrence of rectal cancer, with 35.2% receiving palliative RT and 71.4% having RT prior to additional resection with a 1.6% 30-day mortality rate. Only 17% of patients had RT prior to the recurrence, either preoperative (8%) or postoperative (9%) at the time of the treatment of the primary tumor. Patients received 50 Gy if they received definitive RT and 30 Gy if palliative RT. Patients undergoing an R0 resection had a 55% survival rate as compared to 20% if undergoing an R1 resection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Every effort should be made to obtain an R0 resection. Most studies have found completeness of resection to be an independent prognostic variable for survival.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients selected for this experimental approach might include those with locally recurrent disease alone or in combination with metastatic cancer, when suffering from intractable pain and/or bleeding. They should have a Karnofsky performance status (KPS) of &amp;ge;70% and have no prior history of bowel obstruction within the pelvis. The optimal reirradiation dose has yet to be determined; however, final cumulative dose decisions should be determined based on the initial radiation dose given, the amount of small bowel in the radiation treatment field, the distance in time to recurrence, and the volume previously treated, as well as the intended volume to be retreated with irradiation. Reirradiation doses exceeding 50 Gy were found to significantly increase the infield progression-free survival. When reirradiating the pelvis, every effort should be made to limit the dose to the bowel or bladder (see Variant 3 above).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Review of Intraoperative Radiation Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;IORT provides an additional therapy option in patients with locally recurrent rectal cancer, including those who have received prior external beam pelvic radiation. IORT involves radiation treatment delivered during a surgical procedure to the tumor bed, with the advantage of sparing surrounding normal tissues. Radiation is delivered either by a linear accelerator, resulting in the production of electron beams (intraoperative radiation therapy [IOERT]), or in the form of either low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy. LDR brachytherapy involves permanent placement of radioactive I-125 or Pd-103 seeds in the tumor bed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;HDR brachytherapy uses a machine housing a high-activity Ir-192 source that can be connected to a multichannel applicator that can conform to the tumor bed. With HDR-IORT, the dose distribution (depth and location) can be individualized by altering source dwell positions. A dose of 10-20 Gy can be delivered over several minutes, compared to hours with LDR brachytherapy. IOERT has been used in an effort to improve local control and quality of life. It requires less planning and setup time when compared to HDR-IORT; however, it is more challenging for treating larger areas, and dosimetry planning is not as reliable. Ideally, each department could benefit from the flexibility of having both HDR-IORT and IOERT in order to accommodate diverse cases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Intraoperative Radiation Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One study reported that the extent of surgical resection was the most important factor for improving local control in patients undergoing IORT, with a local control rate of 50% and a 2-year actuarial local relapse-free survival rate of 56% reported in this group of patients. Overall, including patients unable to undergo a complete resection, the 2-year actuarial local relapse-free survival rate was only 14%. Use of IOERT with close or positive resection margins has historically resulted in inferior outcomes in patients with locally recurrent rectal cancer. A group of researchers reported on 57 patients receiving reirradiation of 30.6 Gy with IOERT. The IOERT dose was dependent upon the completeness of resection, with patients having an R0 resection receiving 10 Gy, patients with an R1 resection receiving 12.5 Gy, patients with an R2 resection and &amp;lt;2 cm residual receiving 15 Gy, and those with &amp;ge;2 cm receiving 17.5 Gy. The 5-year overall survival rate was 48.4% in those patients undergoing a R0 resection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients undergoing a radical resection and the stage of the primary tumor were the only factors predicting overall survival in multivariate analysis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Another group of authors reported 3-year and 5-year rates of local control to be 49% and 34%, respectively, in patients receiving 10 Gy IOERT and 50 Gy external beam radiation therapy (EBRT). Once again, those patients undergoing complete resection fared better than those with an incomplete resection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In one of the largest studies to date, one group reported on a series of 607 patients with recurrent colorectal cancer who received IOERT (median: 15, range: 7.5 to 30 Gy) as a component of their treatment. As a component of their treatment, 96% had EBRT, with a median 45.5 Gy, and 37% had an R0 resection. Survival rates at 5 years and 10 years were 30% and 16%, respectively. Central and local relapse was more common in patients with previous RT and with subtotal resection. Grade 3 and higher toxicity was attributable to IOERT in 11% of patients. Neuropathy was seen in 15% of patients and increased with IOERT doses &amp;gt;12.5 Gy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recurrence was found to be higher in a series of patients undergoing retreatment for recurrent rectal cancer if they had an R1 or R2 resection as compared to an R0 resection. Reirradiation was incorporated with regional hyperthermia in 24 patients with recurrent rectal cancer. Patients received a median dose of 39.6 (range, 30-45) Gy combined with 5-FU. The local progression-free survival time was 15 months with a 1-year overall survival rate of 87% and a 1-year local progression-free survival rate of 61%, and 12.5% of patients had a grade 5 acute toxicity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although another study reported a 27% local control rate in 11 patients treated with IORT, having received earlier EBRT, they also reported a high morbidity rate. In addition, another group reported a 4.8% mortality rate, another study had 17 of 25 patients with postoperative morbidity, and an additional study had an 81% surgical morbidity rate, emphasizing that this procedure needs to be performed in highly selected patients with good performance status. Multiple single-institution studies have now demonstrated improved local control and, in some cases, improved survival when IORT is combined with preoperative chemoradiation and aggressive surgery.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A group of researchers found that neoadjuvant EBRT given either prior to or after IOERT resulted in significantly increased rates of free margins (52% versus 24%) in a series of 97 patients treated with locally recurrent rectal cancer. Resection margin status was the strongest prognostic factor for overall survival. The 90-day postoperative mortality was 3.1%.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A number of photon intraoperative systems have been introduced recently. One group of investigators treated patients with recurrent rectal cancer with 5 Gy postoperatively to a depth of 1 cm with a commercially available photon radiosurgery system. The surface dose ranged from 13.4 to 23.1 Gy. A 43% 3-year overall survival rate was noted for patients with recurrent disease. The authors reported no intraoperative complications but did report that hydronephrosis after IORT occurred in 24% of patients, but 7 of 10 of these patients also had concomitant disease recurrence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additional studies are needed to determine how to optimally combine EBRT and IORT with modern systemic chemotherapy to improve quality of life, limit toxicity, and improve survival in patients with recurrent rectal cancer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;High-Dose-Rate Intraoperative Radiation Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;One study reported a 14% local failure rate within the HDR-IORT field in 37 patients with close or positive margins following resection. Therefore, controversy exists as to the importance of final margin status in patients undergoing HDR-IORT. Another study had 12 of 160 patients with recurrent rectal cancer receive 10 Gy of HDR-IORT. The presence of involved lymph nodes, the use of HDR-IORT and an R1 resection resulted in impaired survival. The poor survival is most likely a result of use of HDR-IORT in patients not obtaining a R0 resection.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Permanent Seed Implants&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Another method of IORT is the use of permanent I-125 seeds. One group of researchers treated 13 patients with a median minimal peripheral dose of 140 Gy (range: 120 to 160) with a median pain-free interval of 7 (range: 0 to 14) months. All but one of the patients in the study had received previous radiation, with four patients receiving radiation twice with doses ranging from 80 Gy to 120 Gy. The 1- and 2-year local control rates were 14.4% and 0%, respectively. Grade 4 complications were noted in two patients (15.4%) with one developing a cutaneous fistula and the other a fistula after developing recurrent disease. Five patients developed fibrosis, and one developed perineal edema. All side effects were observed within the first 12 months.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Stereotactic Body Radiation Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stereotactic body radiation therapy (SBRT) has been used to treat well-demarcated lesions in the brain, lung, and liver. It is being used to treat tumors in additional anatomic areas as experience grows in the use of this technique. A group of authors used SBRT to treat 23 patients with nodal recurrence of rectal cancer. They delivered a median dose of 39 Gy (range: 30 to 51) in 3 fractions. They reported an overall survival rate of 25% and a local control rate of 74%. One patient was reported to have severe radiation-related toxicity (see Variant 4 above). Another group treated 14 patients with recurrent rectal cancer who had previously received RT, median 50.4 Gy, with SBRT with either 36 Gy in 3 fractions or a single fraction of 12, 16, or 18 Gy. The 1-year and 2-year local control rates were 90.9% and 68.2%, respectively, with 90% and 79% 1-year and 2-year overall survival rates. None of the patients experienced grade 3 or 4 toxicity and 57% of patients had no pain after the treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patient selection is crucial and should be determined in a multidisciplinary setting prior to offering treatment for recurrent rectal cancer. Patients with central recurrence have been demonstrated to have the best outcome, whereas palliative RT is beneficial for patients with side wall recurrence. Demonstrated expertise in the use of each modality is essential, given the high morbidity rates with IORT.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Particle Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of particle therapy, both proton and carbon ion, has been investigated in the treatment of recurrent rectal cancer with the advent of new particle facilities worldwide. Particle therapy has the potential advantage of treating the tumor while depositing less radiation around the surrounding tissue, a benefit in previously irradiated tissue. A phase I/II study is planned with increasing doses in the phase I part of the study ranging from 12 x 3 GyE to 18 x 3 GyE. The primary endpoint in this portion of the study will be toxicity as in any phase I study with progression-free survival the primary endpoint in the phase II portion of the study. A comparison of multimodality therapy including 3-D conformal RT, chemotherapy and hyperthermia was performed to carbon ion treatment of patients with locally recurrent rectal cancer who hadn't received previous RT in Japan between two institutions. An 85% 2-year overall survival rate was noted in patients treated with carbon ion therapy. There were no reported acute or late gastrointestinal toxicities but 13 and 10 acute and late skin toxicities, respectively. Another study treated 112 patients with 117 sites of locally recurrent primarily resected rectal cancer. None of the patients experienced any grade 3&amp;ndash;5 acute reactions with a reported local control rate of 70%, 89%, and 97% for patients treated with 67.2 GyE, 70.4 GyE, and 73.6 GyE, respectively. Overall survival rates were 72% and 40% at 3 years and 5 years, respectively, for patients treated with 73.6 GyE. Recently, a group of researchers reported on the use of proton beam therapy in the treatment of seven patients with locally recurrent rectal cancer who previously had been treated with a median of 50.4 Gy. Mean proton therapy dose was 61.2 Gy (RBE) for a total combined dose of 95.4&amp;ndash;151.2 Gy. A total of three acute grade 3 and three late grade four toxicities were reported. Two of six patients with a complete metabolic response had recurred locally, but three of six had complete pain relief, and three had partial pain relief. Further studies are needed to fully define the role of particle therapy in this group of patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summary of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The treatment of patients with recurrent rectal cancer is complex and dependent upon many factors, including but not limited to previous RT to the pelvis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Newer systemic treatments have improved response rates and given physicians more options in the treatment of patients with this difficult situation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of induction chemotherapy prior to RT is an evolving treatment option. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Specialized treatment modalities such as IORT and focused treatments, including SBRT, should be used at institutions with experience in these techniques and preferably in patients enrolled in clinical trials. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preoperative chemotherapy with a 5-FU-based regimen with surgical reevaluation is the most appropriate treatment option in patients with recurrent disease who have not received prior RT. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with good performance status presenting with liver metastasis and who have not had prior RT to the pelvic area may benefit from preoperative chemoradiotherapy followed by reevaluation for surgery and resection of the liver metastasis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduced-dose RT, either given daily or hyperfractionated, combined with chemotherapy and reevaluation for resection, is the preferred choice of treatment in patients with recurrent rectal cancer who have received prior RT to the pelvis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of induction chemotherapy prior to RT may be appropriate for selected patients presenting asymptomatically. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;IORT, either with electron beam or with HDR afterloading catheters, could be used in selected centers with the appropriate experience in patients with unresectable recurrent rectal cancer. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Particle therapy may be an option as additional particle therapy facilities are opened, especially in patients who received previous RT. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;BID, twice daily &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT, computed tomography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EUS, endoscopic ultrasound &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;FOLFOX, folinic acid, 5-fluorouracil, and oxaliplatin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;5-FU, 5-fluorouracil &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;IORT, intraoperative radiation therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;KPS, Karnofsky performance status &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;RT, radiation therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;SBRT, stereotactic body radiation therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Algorithms were not developed from criteria guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Recurrent rectal cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Colon and Rectal Surgery" />
      <FieldValue Value="Gastroenterology" />
      <FieldValue Value="Internal Medicine" />
      <FieldValue Value="Oncology" />
      <FieldValue Value="Radiation Oncology" />
      <FieldValue Value="Radiology" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Health Plans" />
      <FieldValue Value="Hospitals" />
      <FieldValue Value="Managed Care Organizations" />
      <FieldValue Value="Physicians" />
      <FieldValue Value="Utilization Management" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To evaluate the appropriateness of treatment procedures for recurrent rectal cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with recurrent rectal cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Radiation therapy (RT)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;RT alone, to pelvis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;To pelvis with 5-fluorouracil (5-FU)-based chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;To pelvis with folinic acid, 5-FU and oxaliplatin (FOLFOX)-based chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Stereotactic body radiation therapy (SBRT) to rectal lesion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;External beam radiation therapy (EBRT) +/- concurrent chemotherapy with intraoperative radiation therapy (IORT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Permanent radioactive implant of symptomatic lesion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Preoperative RT with or without 5-FU-based chemotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hyper- or standard- dose radiation with 5-FU based chemotherapy followed by reevaluation for surgical resection +/- IORT &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgery&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Preoperative RT +/- 5-FU-based chemotherapy and reevaluation of operability &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Tumor excision and abdominal-perineal resection (APR) before external beam RT &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;No surgery &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Surgery post external beam RT +/- 5-FU + IORT boost &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Resection of primary rectal tumor +/- IORT boost followed by adjuvant chemoradiation (5-FU-based) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Attempted tumor removal with IORT &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reevaluation of operability after permanent implant &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consideration of timing of treatment for liver metastasis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consideration of timing of 5-FU-based chemotherapy &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Local control &lt;/li&gt;&#xA;    &lt;li&gt;2- and 5-year survival rates &lt;/li&gt;&#xA;    &lt;li&gt;Median overall survival time &lt;/li&gt;&#xA;    &lt;li&gt;Relapse-free survival rate&lt;/li&gt;&#xA;    &lt;li&gt;Complete and partial response rate &lt;/li&gt;&#xA;    &lt;li&gt;Treatment-related toxicity&lt;/li&gt;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Literature Search Summary&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Of the 43 citations in the original bibliography, 32 were retained in the final document. Articles were removed from the original bibliography if they were more than 10 years old and did not contribute to the evidence or they were no longer cited in the revised narrative text.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A new literature search was conducted in August 2013 to identify additional evidence published since the &lt;em&gt;ACR Appropriateness Criteria&amp;reg; Recurrent Rectal Cancer&lt;/em&gt; topic was finalized. Using the search strategy described in the literature search companion (see the &quot;Availability of Companion Documents&quot; field), 137 articles were found. Seven articles were added to the bibliography. One hundred thirty articles were not used due to either poor study design, the articles were not relevant or generalizable to the topic, the results were unclear, misinterpreted, or biased, or the articles were already cited in the original bibliography.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The author added 5 citations from bibliographies, Web sites, or books that were not found in the new literature search.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See also the American College of Radiology (ACR) Appropriateness Criteria&amp;reg; literature search process document (see the &quot;Availability of Companion Documents&quot; field) for further information.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Of the 43 citations in the original bibliography, 32 were retained in the final document. The new literature search conducted in August 2013 identified 7 articles that were added to the bibliography. The author added 5 citations from bibliographies, Web sites, or books that were not found in the new literature search.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Study Quality Category Definitions&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 1 - The study is well-designed and accounts for common biases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 2 - The study is moderately well-designed and accounts for most common biases.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 3 - There are important study design limitations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Category 4 - The study is not useful as primary evidence. The article may not be a clinical study or the study design is invalid, or conclusions are based on expert consensus. For example:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;The study does not meet the criteria for or is not a hypothesis-based clinical study (e.g., a book chapter or case report or case series description). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study may synthesize and draw conclusions about several studies such as a literature review article or book chapter but is not primary evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The study is an expert opinion or consensus document. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The topic author assesses the literature then drafts or revises the narrative summarizing the evidence found in the literature. American College of Radiology (ACR) staff drafts an evidence table based on the analysis of the selected literature. These tables rate the study quality for each article included in the narrative.&lt;/p&gt;&#xA;&lt;p&gt;The expert panel reviews the narrative, evidence table and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the variant table(s). Each individual panel member assigns a rating based on his/her interpretation of the available evidence.&lt;/p&gt;&#xA;&lt;p&gt;More information about the evidence table development process can be found in the ACR Appropriateness Criteria&amp;reg; Evidence Table Development documents (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Delphi)" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rating Appropriateness&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American College of Radiology (ACR) Appropriateness Criteria (AC) methodology is based on the RAND Appropriateness Method. The appropriateness ratings for each of the procedures or treatments included in the AC topics are determined using a modified Delphi method. A series of surveys are conducted to elicit each panelist's expert interpretation of the evidence, based on the available data, regarding the appropriateness of an imaging or therapeutic procedure for a specific clinical scenario. The expert panel members review the evidence presented and assess the risks or harms of doing the procedure balanced with the benefits of performing the procedure. The direct or indirect costs of a procedure are not considered as a risk or harm when determining appropriateness. When the evidence for a specific topic and variant is uncertain or incomplete, expert opinion may supplement the available evidence or may be the sole source for assessing the appropriateness.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The appropriateness is represented on an ordinal scale that uses integers from 1 to 9 grouped into three categories: 1, 2, or 3 are in the category &quot;usually not appropriate&quot; where the harms of doing the procedure outweigh the benefits; and 7, 8, or 9 are in the category &quot;usually appropriate&quot; where the benefits of doing a procedure outweigh the harms or risks. The middle category, designated &quot;may be appropriate,&quot; is represented by 4, 5, or 6 on the scale. The middle category is when the risks and benefits are equivocal or unclear, the dispersion of the individual ratings from the group median rating is too large (i.e., disagreement), the evidence is contradictory or unclear, or there are special circumstances or subpopulations which could influence the risks or benefits that are embedded in the variant.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ratings assigned by each panel member are presented in a table displaying the frequency distribution of the ratings without identifying which members provided any particular rating. To determine the panel's recommendation, the rating category that contains the median group rating without disagreement is selected. This may be determined after either the first or second rating round. If there is disagreement after the second rating round, the recommendation is &quot;may be appropriate.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This modified Delphi method enables each panelist to articulate his or her individual interpretations of the evidence or expert opinion without excessive influence from fellow panelists in a simple, standardized and economical process. For additional information on the ratings process see the &lt;a href=&quot;http://www.acr.org/%7E/media/ACR/Documents/AppCriteria/RatingRoundInfo.pdf&quot; title=&quot;ACR Web site&quot;&gt;Rating Round Information&lt;/a&gt; document on the ACR Web site.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Additional methodology documents, including a more detailed explanation of the complete topic development process and all ACR AC topics can be found on the &lt;a href=&quot;http://www.acr.org/Quality-Safety/Appropriateness-Criteria&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt; (see also the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Guideline developers reviewed a published cost analysis.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations are based on analysis of the current literature and expert panel consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Summary of Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Of the 44 references cited in the &lt;em&gt;ACR Appropriateness Criteria&amp;reg; Recurrent Rectal Cancer&lt;/em&gt; document, all of them are categorized as therapeutic references including 15 well-designed studies, 23 good quality studies, and one quality study that may have design limitations. There are 5fivereferences that may not be useful as primary evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Most of the references are well-designed or good quality studies and provide good evidence.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Selection of appropriate procedures for treatment and management of patients with recurrent rectal cancer&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Toxicity of chemotherapy &lt;/li&gt;&#xA;    &lt;li&gt;Adverse effects of radiation therapy include toxicity, bowel obstruction, fistula, neuropathy, fibrosis, perineal edema, diarrhea and hydronephrosis &lt;/li&gt;&#xA;    &lt;li&gt;Complications of surgery &lt;/li&gt;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An American College of Radiology (ACR) Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="End of Life Care" />
      <FieldValue Value="Getting Better" />
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Konski AA, Herman JM, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Fowler KJ, Goodman KA, Jabbour SK, Jones WE III, Koong AC, Kumar R, Lee P, Rodriguez-Bigas M, Small W Jr, Suh WW, Expert Panel on Radiation OncologyâGastrointestinal. ACR Appropriateness CriteriaÂ® recurrent  rectal cancer [online publication]. Reston (VA): American College of Radiology (ACR); 2014. 11 p.  [44 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="1998 (revised 2014)" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="American College of Radiology - Medical Specialty Society" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American College of Radiology (ACR) provided the funding and the resources for these ACR Appropriateness Criteria&amp;reg;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology &amp;ndash; Gastrointestinal&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Panel Members&lt;/em&gt;: Andre A. Konski, MD, MBA, MA (&lt;em&gt;Principal Author&lt;/em&gt;); Joseph M. Herman, MD, MSc (&lt;em&gt;Panel Vice-chair&lt;/em&gt;); May Abdel-Wahab, MD, PhD; Ross A. Abrams, MD; Nilofer Azad, MD; Prajnan Das, MD; Jadranka Dragovic, MD; Kathryn J. Fowler, MD; Karyn A. Goodman, MD; Salma K. Jabbour, MD; William E. Jones III, MD; Albert C. Koong, MD, PhD; Rachit Kumar, MD; Percy Lee, MD; Miguel Rodriguez-Bigas, MD; William Small Jr, MD; W. Warren Suh, MD (&lt;em&gt;Panel Chair&lt;/em&gt;)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xA;&lt;p&gt;This guideline updates a previous version: Konski AA, Suh WW, Blackstock AW, Herman JM, Hong TS, Poggi MM, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Expert Panel on Radiation Oncology-Rectal/Anal Cancer. ACR Appropriateness Criteria&amp;reg; recurrent rectal cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2011. 9 p. [43 references]&lt;/p&gt;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/69498/Narrative&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Overview. Reston (VA): American College of Radiology; 2015 Feb. 3 p. Available from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/Overview.pdf&quot; title=&quot;ACR Web site&quot;&gt;American College of Radiology (ACR) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Literature search process. Reston (VA): American College of Radiology; 2015 Feb. 1 p. Available from the &lt;a href=&quot;http://www.acr.org/~/media/ACR/Documents/AppCriteria/LiteratureSearchProcess.pdf&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg;. Evidence table development. Reston (VA): American College of Radiology; 2015 Nov. 5 p. Available from the &lt;a href=&quot;https://www.acr.org/~/media/ACR/Documents/AppCriteria/EvidenceTableDevelopment.pdf?db=web&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg; recurrent rectal cancer. Evidence table. Reston (VA): American College of Radiology; 2014. 23 p. Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/69498/ET&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ACR Appropriateness Criteria&amp;reg; recurrent rectal cancer. Literature search. Reston (VA): American College of Radiology; 2014. 1 p. Available from the &lt;a href=&quot;https://acsearch.acr.org/docs/69498/LitSearch/&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on March 31, 2003. The information was verified by the guideline developer on April 21, 2003. This summary was updated by ECRI Institute on June 15, 2009. This summary was updated by ECRI Institute on March 27, 2012. This summary was updated by ECRI Institute on August 3, 2015.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Instructions for downloading, use, and reproduction of the American College of Radiology (ACR) Appropriateness Criteria&amp;reg; may be found on the &lt;a href=&quot;http://www.acr.org/Quality-Safety/Appropriateness-Criteria/TermsConditions&quot; title=&quot;ACR Web site&quot;&gt;ACR Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>